Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CXL vs CXL + INTACS for Keratectasia
NCT01081561Phase 3Unknown
- Start
- Jan 2009
- Primary completion
- Dec 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of riboflavin in keratoconus, corneal ectasia. Status: unknown.
02
Drugs
riboflavin
03
Conditions
keratoconuscorneal ectasia
Beyond the preview
Go deeper on NCT01081561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01081561.